Clockwise from L: John Maraganore, Andrew Lo and Mark McClellan

The renowned drug hunter, the Wash­ing­ton in­sid­er, the MIT strate­gist: How did one low-pro­file biotech en­list a dream team of top biotech ad­vi­sors?

When you’re head­ing up a fledg­ling biotech out to make a name for your­self in the mid­dle of a wild in­dus­try boom, there’s one sure way to dif­fer­en­ti­ate your­self that’s bound to at­tract uni­ver­sal nods.

It doesn’t in­volve lots of mon­ey — plen­ty of that go­ing around — and it isn’t con­strained by time­lines.

You en­list some great sci­en­tists, and you put to­geth­er a dream team of high-pro­file in­dus­try lead­ers to men­tor you through the long and ar­du­ous process of drug de­vel­op­ment ahead.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.